Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05091437
Other study ID # D133FR00176
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date December 30, 2021
Est. completion date June 30, 2025

Study information

Verified date June 2024
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Early diagnosis of LC in the asymptomatic stage through intentional screening programs and/or incidental pulmonary nodule identification and follow-up are known to improve outcomes significantly. There are large gaps in the screening and early detection of LC, especially in LMIC - driven by multifactorial aspects, including a variety of socioeconomic and infrastructural factors, mainly due to limitations in the required network of specialized human resources and technical capacity. Identifying LC at an early stage allows for treatment that is more likely to be curative, thereby improving survival. The present study aims to characterize the lung nodule journey in different hospitals/clinics across Latin America, describing the use of health resources, time to diagnosis, stage at diagnosis, and time to treatment depending on the source of nodule identification in two different cohorts (retrospective and prospective).


Description:

This non-interventional observational study will capture data (retrospective and prospective cohorts) from around 20 to 25 hospitals/clinics to report lung nodules (patients' journey) in Latin America. Objectives and Hypotheses: Primary objective • To describe the lung nodule patient journey from the time of nodule identification through its final diagnosis, staging, and treatment decision. Note: Lung nodules identified from different settings would be nodules identified incidentally and in lung cancer screening programs. Secondary objective(s) - To determine the medical specialties involved in the lung nodule study journey. - To describe a medical specialist who first identifies the lung nodule (referral patterns). - To estimate the proportion of benign and malignant nodules. - To understand health care resource utilization from nodule detection to final diagnosis and management. - Time from nodule identification until a final diagnosis and treatment decision. - Treatment decision and specialties involved in the decision. Study Population: Adult ≥ 35 years of age with solid or subsolid (part solid, pure ground glass) lung nodules identified in different settings, including nodules identified incidentally and nodules identified in lung cancer screening programs could be targeted. The study population will comprise two cohorts, one prospective for subjects starting the study of pulmonary nodules since site activation and onwards, and other retrospective for subjects who started the study of pulmonary nodules from March 2019.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 562
Est. completion date June 30, 2025
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender All
Age group 35 Years to 100 Years
Eligibility Inclusion Criteria: - Adult subjects (= 35 years of age) - a) Prospective cohort: All eligible subjects with solid or subsolid (part solid, pure ground glass) lung nodule identified in imaging exams in routine clinical practice, prior to 30 days of informed consent given [please refer to: Fleischner Society 2017 guidelines for nodules size and definition (= 6 mm and < 3 cm)) for subject inclusion]. Subjects identified from different sources (Nodules identified incidentally and in lung cancer screening programs) will be considered OR b) Retrospective cohort: All eligible subjects with solid or subsolid (part solid, pure ground glass) lung nodule identified in the past; more preciously from March 2019 to the study initiation date. [Please refer to: Fleischner Society 2017 guidelines for nodules size and definition (= 6 mm and < 3 cm) for subject inclusion]. - Written informed consent to have medical data collected and stored for the prospective cohort and as guided by the local regulations for the retrospective cohort.. Exclusion Criteria: - Subjects unable to undergo any lung diagnostic procedure. - Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years or are deemed by the investigator to be at low risk for recurrence of that malignancy - Subjects with calcified lung nodules with an established diagnosis

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Observational study
Incidental lung nodules identification

Locations

Country Name City State
Argentina Research Site Caba
Brazil Research Site Porto Alegre
Brazil Research Site Rio de Janeiro
Brazil Research Site Sao Paulo
Chile Research Site Antofagasta
Chile Research Site Concepcion
Colombia Research Site Bogota
Colombia Research Site Cundinamarca
Costa Rica Research Site San Jose
Dominican Republic Research Site Santo Domingo
Mexico Research Site Estado de Mexico
Mexico Research Site Mexico City
Mexico Research Site Monterrey Nuevo Leon
Panama Research Site Panama

Sponsors (2)

Lead Sponsor Collaborator
AstraZeneca INCUNA (Scientific and Technical partner)

Countries where clinical trial is conducted

Argentina,  Brazil,  Chile,  Colombia,  Costa Rica,  Dominican Republic,  Mexico,  Panama, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time of nodule identification up to diagnosis and treatment Description of the lung nodule patient journey from the time of nodule identification through its final diagnosis, staging, and treatment decision. 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT06056999 - New Method to Differentiate Benign and Malignant Pulmonary Nodules.
Recruiting NCT04182893 - Clinical Study of ctDNA and Exosome Combined Detection to Identify Benign and Malignant Pulmonary Nodules
Active, not recruiting NCT03651986 - Diagnostic and Monitoring Significance of ctDNA Methylation Analysis by NGS in Benign and Malignant Pulmonary Nodules
Not yet recruiting NCT05067023 - Evaluation for Benign and Malignant Pulmonary Ground-glass Nodules Based on MRI Dynamic Contrast Enhanced Imaging N/A
Completed NCT02146131 - Ultrathin Bronchoscope and Radial Endobronchial Ultrasound (R-EBUS) With Fluoroscopy Versus Standard Fiberoptic Bronchoscopy (FB) (P00029233 ) N/A
Recruiting NCT04462185 - A Prospective Cohort Study of Chinese Patients With Pulmonary Nodules: Prediction of Lung Cancer Using Noninvasive Biomarkers
Recruiting NCT04690790 - Pulmonary Nodule Localization Prospective Validation
Recruiting NCT05525260 - Limonene for Pulmonary Nodule Chemoprevention Phase 2
Completed NCT00629460 - A Pilot Study of PET-CT in the Assessment of Pulmonary Nodules in Children With Malignant Solid Tumors N/A
Completed NCT03420885 - Effects of Ba Duan Jin for Patients With Pulmonary Nodules N/A